J.Safra Asset Management Corp Purchases New Stake in Vaxcyte, Inc. $PCVX

J.Safra Asset Management Corp acquired a new position in shares of Vaxcyte, Inc. (NASDAQ:PCVX) during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 12,564 shares of the company’s stock, valued at approximately $730,000.

Other large investors have also recently bought and sold shares of the company. Janus Henderson Group PLC lifted its holdings in Vaxcyte by 23.8% in the first quarter. Janus Henderson Group PLC now owns 16,575,875 shares of the company’s stock valued at $960,231,000 after acquiring an additional 3,188,687 shares during the period. T. Rowe Price Investment Management Inc. grew its stake in shares of Vaxcyte by 35.9% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 11,296,333 shares of the company’s stock worth $521,213,000 after purchasing an additional 2,981,038 shares during the period. Wellington Management Group LLP grew its stake in shares of Vaxcyte by 18.5% during the 4th quarter. Wellington Management Group LLP now owns 5,966,310 shares of the company’s stock worth $275,286,000 after purchasing an additional 933,539 shares during the period. State Street Corp increased its holdings in shares of Vaxcyte by 4.1% in the 4th quarter. State Street Corp now owns 4,980,005 shares of the company’s stock valued at $229,777,000 after purchasing an additional 194,116 shares in the last quarter. Finally, Paradigm Biocapital Advisors LP increased its holdings in shares of Vaxcyte by 7.5% in the 4th quarter. Paradigm Biocapital Advisors LP now owns 4,068,020 shares of the company’s stock valued at $187,698,000 after purchasing an additional 283,265 shares in the last quarter. Hedge funds and other institutional investors own 96.78% of the company’s stock.

Analyst Ratings Changes

Several brokerages recently commented on PCVX. Wall Street Zen upgraded shares of Vaxcyte from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 8th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vaxcyte in a report on Monday, July 6th. Finally, Zacks Research upgraded shares of Vaxcyte from a “strong sell” rating to a “hold” rating in a research report on Wednesday, August 12th. Five investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $86.00.

Insider Buying and Selling at Vaxcyte

In other Vaxcyte news, COO Jim Wassil sold 2,250 shares of Vaxcyte stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $49.52, for a total transaction of $111,420.00. Following the completion of the transaction, the chief operating officer owned 158,494 shares in the company, valued at approximately $7,848,622.88. The trade was a 1.40% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Harpreet S. Dhaliwal sold 17,000 shares of the company’s stock in a transaction dated Wednesday, August 5th. The shares were sold at an average price of $55.00, for a total transaction of $935,000.00. Following the completion of the sale, the insider directly owned 76,756 shares in the company, valued at $4,221,580. This trade represents a 18.13% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 120,646 shares of company stock valued at $6,570,810. Insiders own 3.30% of the company’s stock.

Vaxcyte Stock Performance

PCVX opened at $58.07 on Monday. The company has a market cap of $8.64 billion, a price-to-earnings ratio of -7.61 and a beta of 1.23. Vaxcyte, Inc. has a one year low of $29.87 and a one year high of $65.00. The business’s fifty day moving average is $54.95 and its two-hundred day moving average is $55.53.

Vaxcyte (NASDAQ:PCVX) last announced its quarterly earnings results on Wednesday, August 5th. The company reported ($1.97) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.06) by $0.09. During the same period in the previous year, the firm posted ($1.22) earnings per share. On average, analysts predict that Vaxcyte, Inc. will post -7.65 EPS for the current fiscal year.

About Vaxcyte

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.